0 82

Cited 0 times in

Management of HER2 alterations in non-small cell lung cancer - The past, present, and future

Authors
 Jorn Nützinger  ;  Jii Bum Lee  ;  Jia Li Low  ;  Puey Ling Chia  ;  Silvana Talisa Wijaya  ;  Byoung Chul Cho  ;  Sun Min Lim  ;  Ross A Soo 
Citation
 LUNG CANCER, Vol.186 : 107385, 2023-12 
Journal Title
LUNG CANCER
ISSN
 0169-5002 
Issue Date
2023-12
MeSH
Antineoplastic Agents* / pharmacology ; Antineoplastic Agents* / therapeutic use ; Carcinoma, Non-Small-Cell Lung* / drug therapy ; Carcinoma, Non-Small-Cell Lung* / genetics ; Carcinoma, Non-Small-Cell Lung* / pathology ; Humans ; Lung Neoplasms* / drug therapy ; Lung Neoplasms* / genetics ; Lung Neoplasms* / pathology ; Mutation ; Receptor, ErbB-2 / genetics ; Trastuzumab / genetics ; Trastuzumab / therapeutic use
Keywords
Exon 20 mutation ; HER2 ; Non-small cell lung cance r ; Targeted therapy
Abstract
HER2 mutations, which account for 2–4% of non-small cell lung cancer (NSCLC), are distinct molecular alterations identified via next generation sequencing (NGS). Previously, treatment outcomes in HER2-mutant metastatic NSCLC were dismal, showing limited clinical benefit with platinum-based chemotherapy with or without immunotherapy. In contrast to HER2-altered breast and gastric cancer, HER2-mutant NSCLC does not benefit from HER2 targeting agents such as trastuzumab or TDM1. HER2 mutations are also inherently different from HER2 overexpression and amplification. Currently, trastuzumab deruxtecan, a HER2 targeting antibody drug conjugate (ADC) is the first and only approved treatment option for patients with HER2-mutant metastatic NSCLC after failure with standard treatment. In this review, we summarized the biology of HER2 and detection of HER2 overexpression, amplification and mutations, as well as general landscape of landmark and ongoing clinical trials encompassing from chemotherapy to targeted agents, including tyrosine kinase inhibitors (TKIs), ADCs and investigational agents. © 2023 Elsevier B.V.
Full Text
https://www.sciencedirect.com/science/article/pii/S0169500223009236
DOI
10.1016/j.lungcan.2023.107385
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Lim, Sun Min(임선민)
Cho, Byoung Chul(조병철) ORCID logo https://orcid.org/0000-0002-5562-270X
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/198104
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links